Miltefosine is an alkylphosphocholine drug with demonstrated activity against various
parasite species and cancer cells as well as some pathogenic bacteria and fungi. For 10 …

This mini-review focuses on leishmanicidal drugs that were sourced from small molecules
previously approved for other diseases. The mechanisms of action of these molecules are …

The current treatments for visceral leishmaniasis are old and toxic with limited routes of
administration. The emergence of drug-resistant Leishmania threatens the efficacy of the …

Objectives Candida auris (C. auris) is an emerging fungal species that is able to develop
multidrug resistance and outbreaks of invasive infections worldwide with high mortality rates …

Anti-microbial peptides (AMPs), small biologically active molecules, produced by different
organisms through their innate immune system, have become a considerable subject of …

Acanthamoeba keratitis is a sight-threatening infectious disease. Resistance of the cystic
form of the protozoan to biocides and the potential toxicity of chemical compounds to corneal …

Introduction Candida auris is responsible for hospital outbreaks worldwide. Some C. auris
isolates may show concomitant resistance to azoles, echinocandins, and polyenes, thereby …

Bromopyruvate (3BP) is an energy-depleting drug that inhibits Hexokinase II activity by
alkylation during glycolysis, thereby suppressing the production of ATP and inducing cell …

Abstract Miltefosine (MT)(hexadecylphosphocholine) was implemented to cope with
resistance against antimonials, the classical treatment in Leishmaniasis. Given the scarcity …

Miltefosine (MLT) is an alkylphosphocholine with clinical success as an anticancer and
antiparasitic drug. Although the mechanism of action of MLT is highly debated, the …